SCHEMBL7420765

SCHEMBL7420765

O=[N+]([O-])c1cc(F)cc(Br)c1I

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.41
ATM Q13315 1/20 0.41
ALDH1A1 P00352 4/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 4/20 0.38
PKM P14618 1/20 0.38
P2RY6 Q15077 1/20 0.38
MAPK1 P28482 2/20 0.37
HIF1A Q16665 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TTR P02766 2/20 0.36
CYP1A2 P05177 1/20 0.35
CTSB P07858 1/20 0.35
VCAM1 P19320 1/20 0.34
PDE7A Q13946 1/20 0.34
KCNMA1 Q12791 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7648574 0.80 ERN1 (0.44) ALDH1A1CYP3A4MAPTPKMHTT
SCHEMBL2132590 0.80 TDP1 (0.44) TDP1ATMALDH1A1CYP3A4MAPT
SCHEMBL29617721 0.80 TDP1 (0.44) TDP1ATMALDH1A1CYP3A4MAPT
SCHEMBL631164 0.78 ALDH1A1 (0.63) TDP1ATMALDH1A1CYP3A4MAPT
SCHEMBL18964368 0.78 ALDH1A1 (0.63) TDP1ALDH1A1CYP3A4MAPTMAPK1
SCHEMBL18496986 0.77 ATM (0.48) TDP1ATMALDH1A1CYP3A4MAPT
SCHEMBL30155391 0.77 CYP1A2 (0.52) TDP1ATMALDH1A1CYP3A4MAPT
SCHEMBL993946 0.77 CYP1A2 (0.52) TDP1ATMALDH1A1CYP3A4MAPT
SCHEMBL103118 0.77 TTR (0.50) TDP1ALDH1A1MAPTMAPK1HIF1A
SCHEMBL16972863 0.77 TDP1 (0.47) TDP1ATMALDH1A1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186425-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2025-06-12 US disclosed
EP-4490147-A1 PPARG INVERSE AGONISTS AND USES THEREOF Flare Therapeutics Inc. (US) 2025-01-15 EP disclosed
CN-118984823-A PPARG inverse agonists and uses thereof 弗拉雷治疗公司 2024-11-19 CN disclosed
WO-2023172845-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. (US) 2023-09-14 WO disclosed
US-5547991-A NMDA antagonism method MERRELL PHARMACEUTICALS INC. (US) 1996-08-20 US disclosed
US-5484814-A NMDA antagonists MERRELL DOW PHARMACEUTICALS INC. (US) 1996-01-16 US disclosed
US-5470870-A New class of excitatory amino acid antagonist for epilepsy, anxiety or stroke MERRELL DOW PHARMACEUTICALS INC. (US) 1995-11-28 US disclosed
EP-0501378-B1 NMDA Antagonists MERRELL DOW PHARMA (US) 1995-01-11 EP disclosed
US-5360814-A NMDA antagonists MERRELL DOW PHARMACEUTICALS INC. (US) 1994-11-01 US disclosed
EP-0501378-A1 NMDA Antagonists MERRELL DOW PHARMACEUTICALS INC. (US) 1992-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186425-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD TDP1 3127/4885ATM 2659/4885ALDH1A1 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.